Review: Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes

被引：2
作者：
Chatterjee, Saurav [1 ,2 ]
Chatterjee, Sanjay [3 ]
机构：
[1] Brown Univ, Providence, RI 02912 USA
[2] Providence VAMC, Providence, RI USA
[3] Apollo Gleneagles Hosp, Kolkata, W Bengal, India
来源：
ANNALS OF INTERNAL MEDICINE | 2013年 / 158卷 / 08期
关键词：
METAANALYSIS;
D O I：
10.7326/0003-4819-158-8-201304160-02008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
[31]   Systematic review and meta-analysis: dipeptidyl peptidase-4 inhibitors and rheumatoid arthritis risk [J].
Wang, Miao ;
Li, Muqin ;
Xie, Ying .
ENDOCRINE JOURNAL, 2021, 68 (06) :729-738
[32]   Dipeptidyl peptidase-4 inhibitors and bone metabolism: is vitamin D the link? [J].
Barchetta, I. ;
Cimini, F. A. ;
Bloise, D. ;
Cavallo, M. G. .
ACTA DIABETOLOGICA, 2016, 53 (05) :839-844
[33]   Acquired Hemophilia A Associated with Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Single-Center Case Series in Japan [J].
Yamasaki, Satoshi ;
Kadowaki, Masanori ;
Jiromaru, Takashi ;
Takase, Ken ;
Iwasaki, Hiromi .
DIABETES THERAPY, 2019, 10 (03) :1139-1143
[34]   The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis [J].
Chen, Maosheng ;
Liu, Yueming ;
Jin, Juan ;
He, Qiang .
RENAL FAILURE, 2016, 38 (04) :581-587
[35]   An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease [J].
Singh-Franco, Devada ;
Harrington, Catherine ;
Tellez-Corrales, Eglis .
SAGE OPEN MEDICINE, 2016, 4
[36]   Dipeptidyl peptidase-4 inhibitors versus sulfonylureas on the top of metformin in patients with diabetes and acute myocardial infarction [J].
Her, Ae-Young ;
Choi, Byoung Geol ;
Rha, Seung-Woon ;
Kim, Yong Hoon ;
Jeong, Myung Ho .
CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2024, 14 (01) :38-50
[37]   Prevalence of diabetes mellitus in bullous pemphigoid patients in the absence of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis [J].
William Guo ;
Sourish Rathi ;
Jocellie Marquez ;
Holly Smith ;
Annet Kuruvilla ;
Marcia G. Tonnesen ;
Joann N. Salvemini .
Archives of Dermatological Research, 2023, 315 :2207-2213
[38]   Prevalence of diabetes mellitus in bullous pemphigoid patients in the absence of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis [J].
Guo, William ;
Rathi, Sourish ;
Marquez, Jocellie ;
Smith, Holly ;
Kuruvilla, Annet ;
Tonnesen, Marcia G. ;
Salvemini, Joann N. .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2023, 315 (08) :2207-2213
[39]   The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors [J].
Ling, Ann Wan-Chin ;
Chan, Cze-Ci ;
Chen, Shao-Wei ;
Kao, Yi-Wei ;
Huang, Chien-Ying ;
Chan, Yi-Hsin ;
Chu, Pao-Hsien .
CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
[40]   Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis [J].
Chen, Y. ;
Men, K. ;
Li, X. -F. ;
Li, J. ;
Liu, M. ;
Fan, Z. -Q. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (11) :3502-3514
12345